Table 4

 Statistically significant correlations of per cent change in biomarker levels from baseline, with clinical end points*

TreatmentEfficacy parameterr Valuep Value
*Only statistically significant correlations are shown.
ACR20, American College of Rheumatology 20% improvement; ACR50, American College of Rheumatology 50% improvement; DAS28, Disease Activity Score based on 28 joints; ICAM-1, intracellular adhesion molecule-1; IL8, interleukin 8; SHS, Sharp score with the van der Heijde modification.
Infliximab (n = 11)
    Week 14
    Week 16
Etanercept (n = 12)
    Week 14